Agree wholeheartedly.
Most biotech's have a pretty clear path forward - you know it's going to be x months/years for resuIts, and that CRs are needed to progress. What makes BOT different is Permetrex. It's the great unknown. Maybe they pull in Permetrex deal before Christmas which would change the game. Maybe they never sign anyone up. It's this X factor which makes BOT less predictable.
Ann: Ethics Approval for BTX 1308 Psoriasis Patient Study Secured, page-24
-
- There are more pages in this discussion • 95 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.010(2.78%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.0¢ | 33.5¢ | $2.103M | 6.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 32406 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 234417 | 5 |
View Market Depth
| Last trade - 16.10pm 02/12/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
